Tag: Alzheimer’s
Distance to Neurologist, PCP May Explain Alzheimer Disease Disparities
Non-Hispanic American Indian and/or Alaska Native and Hispanic decedents have to travel further to neurologist than non-Hispanic Whites
FDA Delays Decision on New Alzheimer’s Drug
Harmful Association Identified Between Traffic Pollution, Amyloid Plaques
Strongest association seen between fine particulate matter and neuropathology was among those without APOE ε4 alleles
Timing of CSF Biomarker Divergence for Alzheimer Disease, Normal Cognition Varies
Estimated times of divergence of cerebrospinal fluid biomarkers vary from 18 years for Aβ42 to six years for cognitive decline
Lower Alzheimer Risk Seen With PDE5i Initiation for Erectile Dysfunction
Greatest reduction in risk seen for those receiving 21 to 50 phosphodiesterase type 5 inhibitor prescriptions
Biogen Is Dropping Controversial Alzheimer’s Drug Aduhelm
Strategies Needed to Improve Delivery of Alzheimer Disease-Modifying Therapies
Models that enable primary care practitioners to diagnose and evaluate patients for treatment eligibility would have biggest impact on wait times
Monoclonal Antibodies Provide Small Benefits in Alzheimer Disease
Harms include increased risks for amyloid-related imaging abnormalities (ARIA)-edema, ARIA-hemorrhage, and symptomatic ARIA-edema
Study IDs Proportion of Dementia Cases Attributable to Known Risk Factors
PAF for nongenetic risk factors combined similar for men and women, but varies across racial, ethnic groups
Racial/Ethnic Minorities Underrepresented in Alzheimer Neuroimaging Research
Sample diversity has improved recently, with proportion of Blacks increasing from 3.39 percent in 1994-2017 to 8.29 percent in 2018-2022
